Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region
SECOVtx
1 other identifier
observational
300
1 country
1
Brief Summary
Goal of this study is to evaluate the seroprevalence of anti-SARS-CoV-2 antibodies in patients after kidney transplantation who are one of the risk groups for the severe course of the infection and map the progression of the virus throughout this specific part of population, which is also important for possible future epidemics. We will evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to age and gender. We will compare seroprevalence in all measured antibodies types and we will also assess the development of antibodies level in positive patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 30, 2021
CompletedStudy Start
First participant enrolled
April 30, 2021
CompletedFirst Posted
Study publicly available on registry
May 6, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2022
CompletedDecember 7, 2022
December 1, 2022
1.5 years
April 30, 2021
December 6, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants with positive anti-SARS-CoV-2 antibodies (one or more)
Seroprevalence of anti-SARS-Cov 2 antibodies - in how many patients is positive at least one of the measured antibodies against SARS-Cov-2 virus (IgA, IgM or IgG against RBD, IgG against nucleocapsid).
Between 18 January 2020 and 30 September 2022
Secondary Outcomes (2)
Number od Participants with change of baseline of anti-SARS-COV-2 antibodies
From May 1, 2021 to September 30, 2022
Number of Participants with positive anti-SARS-COV-2 antibodies in groups divided by age, sex, blood type.
Between 18 January 2020 and 30 September 2022
Study Arms (1)
Kidney transplant recipients
Collection of data from kidney transplant patients at regular outpatient check-ups.
Interventions
Eligibility Criteria
Patients after any kidney transplantation, monitored regularly in the nephrology clinic of the University Hospital Ostrava.
You may qualify if:
- Age ≥ 18
- Recipient of a transplanted kidney
- Planned visit to the outpatient nephrology clinic of University Hospital Ostrava, Czech Republic, between 1.5. and 30.7.2021 for enrolment
- Planned blood collection and available results of blood tests from planned inspections from 18.1.2021.
- Signed consent to the use of anonymous data for scientific purposes and publications.
You may not qualify if:
- disagreement with participation in the study and data analysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Ostrava
Ostrava, 70852, Czechia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jan Vaclavik, prof.,M.D.
University Hospital Ostrava
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 30, 2021
First Posted
May 6, 2021
Study Start
April 30, 2021
Primary Completion
October 30, 2022
Study Completion
October 30, 2022
Last Updated
December 7, 2022
Record last verified: 2022-12